No effectiveness and safety data, such as a change in eGFR, urinary albumin-to-creatinine ratio, kidney failure, injury and death, the occurrence of fatal adverse events and adverse events leading to discontinuation of treatment, as well as health-related quality of life in the population of patients with CKD treated with MRAs were available. Here, ALB is linked to chronic kidney disease.